This new composition of matter is a Intranasal multivalent vaccine candidates for both SARS-CoV-2 and RSV. This vaccine platform uses attenuated measles (MeV) and mumps (MuV) virus vectors to deliver optimized SARS‑CoV‑2 and RSV antigens. The intranasal multivalent vaccine was developed in response to the ongoing challenges posed by rapidly evolving COVID‑19 variants and the lack of effective RSV vaccines for infants and children.